The occurrence and risk factors associated with post-traumatic stress disorder among discharged COVID-19 patients in Tianjin, China

Zaoxian Mei1 | Xiaohui Wu3 | Xueli Zhang1 | Xingjie Zheng1 | Wenxin Li1 | Rui Fan1 | Hongwei Yu1 | Shunming Zhang2 | Yeqing Gu2 | Xuena Wang2 | Yang Xia2 | Ge Meng2 | Jun Shen1 | Kaijun Niu2

1 Department of Tuberculosis, Tianjin Haihe Hospital, Tianjin Institute of Respiratory Diseases, No.890 JinGu Road, Jinnan District, Tianjin 300350, China
2 Nutritional Epidemiology Institute and School of Public Health, Tianjin Medical University, No.22 Qixiangtai Road, Heping District, Tianjin 300070, China
3 Tianjin Key Laboratory on Technologies Enabling Development of Clinical, Therapeutics and DiagnosticsCollege of PharmacyTianjin Medical University, No.22 Qixiangtai Road, Heping District, Tianjin 300070, China

Background: Post-traumatic stress disorder (PTSD) is a serious mental health condition that is triggered by a terrifying event. We aimed to investigate the occurrence and risk factors of PTSD among discharged COVID-19 patients.

Methods: This study included 144 discharged COVID-19 patients. PTSD was assessed by using validated cut-offs of the impact of event scale-revised (IES-R, score ≥25). All patients completed a detailed questionnaire survey, and clinical parameters were routinely measured in the hospital. Binary logistic regression models were applied to identify factors associated with PTSD.

Results: Of the 144 participants with laboratory-confirmed COVID-19, the occurrence of PTSD was 16.0%. In multivariable analyses, age above 40 years (adjusted OR [95% CI], 5.19 [2.17–12.32]), female sex (adjusted OR [95% CI], 7.82 [3.18–18.21]), current smoker (adjusted OR [95% CI], 6.72 [3.23–15.26]), and ≥3 involved pulmonary lobes (adjusted OR [95% CI], 5.76 [1.19–15.71]) were significantly associated with a higher risk of PTSD. Conversely, history of hypertension and serum hemoglobin levels were significantly associated with a lower risk of PTSD with adjusted ORs (95% CI) of 0.37 (0.12–0.87) and 0.91 (0.82–0.96), respectively.

Conclusion: Old age, gender (being female), current smoking, bacterial pneumonia, and ≥3 involved pulmonary lobes were associated with an increased occurrence of PTSD among discharged COVID-19 patients.

Keywords: COVID-19, post-traumatic stress disorder

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Brain and Behavior published by Wiley Periodicals LLC
1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than 213 countries worldwide, resulting in an ongoing global pandemic. According to the statistics available in Worldometer (Worldometer, 2020), as of July 20, 2020, COVID-19 had caused more than 14 million cases and nearly 610,000 deaths in the world.

The COVID-19 not only affects physical health but also causes mental health problems (Talevi et al., 2020; Vindegaard & Benros, 2020). One of the common psychological problems is post-traumatic stress disorder (PTSD) arising from exposure to trauma (Pfefferbaum & North, 2020). Bo HX et al. reported that 96.2% out of 714 hospitalized stable patients suffered from significant posttraumatic stress symptoms associated with the COVID-19 before discharge (Bo et al., 2020). A previous study in Iraq and Afghanistan found that veterans who reported PTSD have greater difficulties in their romantic relationships, less family cohesion, less social support, poorer social functioning, and lower life satisfaction compared to subjects without PTSD (Tsai et al., 2012). Furthermore, PTSD was associated with attempted suicide and resulted in a high economic burden for society (Galea et al., 2005). Therefore, identifying risk factors of PTSD symptoms in confirmed COVID-19 patients is important for the early detection of at-risk subgroups and potential interventions.

Although several recent studies have investigated the factors associated with PTSD in front-line medical staff (Wang et al., 2020; Wu & Wei, 2020), the general population (Wang et al., 2020), or university students (Tang et al., 2020), few studies have focused on the factors associated with PTSD among confirmed COVID-19 patients. Thus, the related factors of the occurrence of PTSD in patients with confirmed COVID-19 infection are unknown. To our knowledge, only one small cross-sectional study (n = 41) on PTSD in COVID-19 confirmed patients has been performed, demonstrating a prevalence of PTSD symptoms in 5/41 (12.2%) of participants (Qi et al., 2020). However, only non-severe types of COVID-19 cases were included, and the median time interval between hospitalization and PTSD assessment was less than one month. On the other hand, in addition to the traditional risk factors for PTSD such as age, sex, smoking, and alcohol drinking, factors associated with the severity of COVID-19 (including peripheral blood indicators, hospitalization days, severe pneumonia, hypoalbuminemia, liver injury, and other severe complications) and patient metabolic characteristics (e.g., obesity) might be associated with risk of developing PTSD (Lee et al., 2018; Wang et al., 2020). Furthermore, information on personal and family history of diseases was available in this study. Thus, we conducted this prospective study with a relatively long-term follow-up to investigate the factors potentially involved in PTSD among confirmed COVID-19 patients with various clinical types by including numerous predictors.

2 | METHODS

2.1 | Participants

From January 19 to April 30, 2020, a total of 144 participants were recruited from Tianjin Haihe Hospital, which is a designated hospital for COVID-19 in Tianjin, China. This was a convenience sample of survivors. All participants provided written consent and all the protocol of this study was approved by the Institutional Review Board of Tianjin Haihe Hospital.

A SARS-CoV-2 virus-specific real-time reverse transcriptase polymerase chain reaction (RT–PCR) assay of respiratory specimens, including nasal and pharyngeal swabs is routinely used for diagnosis of COVID-19 (Huang et al., 2020). We included all participants with laboratory-confirmed SARS-CoV-2 infection.

2.2 | Assessment of PTSD

PTSD symptoms were assessed using the impact of events scale-revised (IES-R) by telephone follow-up, which was conducted by the same investigator around three months after laboratory-confirmed SARS-CoV-2 infection. The shortest and longest timepoints of the follow-up were 85 days and 93 days, respectively. Since PTSD symptoms usually begin within 3 months of the traumatic incident (Information MH. Post-Traumatic Stress Disorder, 2021), we chose three months as the follow-up timepoint. The IES-R is a validated 22-item self-reporting questionnaire that measures the subjective distress caused by traumatic events. The 22-item scale comprises three subscales: intrusion, avoidance, and hyperarousal, which correspond to the 3 PTSD symptom clusters. Participants were asked to indicate the degree with which they experienced each PTSD symptom in the past week on a 5-point scale: 0 = “Not at all”, 1 = “A little bit”, 2 = “Moderately”, 3 = “Quite a bit”, 4 = “Extremely”. Scores ≥25 were considered to be of clinical concern (Rash et al., 2008). The IES-R is the most widely used measure internationally for the psychological impact of trauma, and high reliability and validity were observed in the Chinese version of the IES-R (Wu & Chan, 2003).

2.3 | Laboratory measurements

Venous blood samples were routinely drawn from each patient in the fasting state at the earliest time points possible upon hospitalization. White blood cell count, lymphocyte count, hemoglobin, red blood cell count, fibrinogen, D-dimer, C-reactive protein (CRP), procalcitonin, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, creatine kinase, creatine kinase isoenzyme, lactate dehydrogenase, myoglobin, creatinine, urea nitrogen, as well as interleukin-6, were measured under standard hospital assays run by the Department of Laboratory Medicine of the hospital.
2.4 | CURB-65 score

Data for the calculation of CURB-65 were recorded at hospital admission. The CURB-65 severity score (range 0–5 points) was calculated by attributing one point to each of the following clinical features present: confusion, urea > 7 mmol/L, respiratory rate ≥30/min, systolic blood pressure < 90 mmHg, and/or diastolic blood pressure 60 mmHg, and age 65 years (Lim et al., 2003).

2.5 | Thin-section CT imaging and scoring

Thin-section computed tomography (CT) scans (Aquilion Prime 128, Canon Medical Systems, Otawara, Japan) were performed in all patients. Thin-section CT was performed from the lung apices to the adrenal glands at full inspiration, and the process was later repeated at full expiration. The CT scanning parameters were: 64 × 0.5 mm collimation, 120 kV, automatic tube current modulation, 0.5 s gantry rotation time. Images were reconstructed with a hybrid iterative reconstruction algorithm (AIDR 3D) at mild settings, and contiguous inspiratory thin-section CT images were obtained with a thickness of 1 mm at 0.8 mm intervals. CT scans were interpreted at window settings that were optimal for lung parenchyma (window level, –600 HU; window width, 1500 HU) and soft tissue (window level, 400 HU; window width, 40 HU). Patients were scanned while lying supine and during full inspiration and expiration. All CTs were scored by two experienced radiologists blinded to laboratory values and the medical history of the participants. Definitions of radiological terms like ground-glass opacity, reticulation, honeycombing, parenchymal bands, consolidation, air trapping, and bronchiectasis were based on the recommendations of the Nomenclature Committee of the Fleischner Society (Hansell et al., 2008).

To quantify the extent of disease, a semi-quantitative CT score was defined as the sum of lung involvement (0, no involvement; 1, < 5% involvement; 2, 5–25% involvement; 3, 26–50% involvement; 4, 51–75% involvement; and 5, > 75% involvement) of each lobe (Chang et al., 2005; Pan et al., 2020).

2.6 | Measurement of other variables

Age, sex, alcohol drinking status (never or drinking), history of diseases (hypertension, diabetes mellitus, and heart disease), hospitalization days, and oxygenation index (OI) were obtained from a detailed questionnaire survey and electronic medical records. Data on smoking status were collected by a question: “Do you usually smoke?” with two response options: yes (current) or no (former/never). Height and body weight were measured with participants wearing light clothes and no shoes. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared (kg/m²).

2.7 | Complication definitions

Severe pneumonia was defined by the 2007 Infectious Disease Society of America/American Thoracic Society (IDSA/ATS) guidelines (Mandell et al., 2007). Two major criteria include the need for invasive mechanical ventilation and septic shock with the need for vasopressors. The minor criteria include respiratory rate ≥30 times per minute, PaO2/FiO2 ratio <250 (or need for noninvasive ventilation), multilobar infiltration, confusion/disorientation, uremia (BUN >20 mg/dL), leukopenia (<4000 cells/mm³ caused by infection), thrombocytopenia (<100,000 cells/mm³), hypothermia (<36°C), and hypotension requiring aggressive fluid resuscitation. The presence of at least one major criterion or three or more minor criteria was defined as severe pneumonia.

The normal range of serum albumin was 35–55 g/L. Based on previous research, hypoalbuminemia was defined as serum albumin level less than 35 g/L (Adogwa et al., 2014; Aldebeyan et al., 2017; Egbert et al., 2020). Acute liver injury was defined as jaundice with a total bilirubin level of ≥3 mg/dL combined with one of the following two abnormal levels of liver enzymes: (Worldometer, 2020) ≥5 times acute increase of the upper limit of the normal range in ALT; (Talevi et al., 2020) ≥2 times of the upper limit of the normal range in AST (Chen et al., 2020).

2.8 | Statistical analysis

Statistical Analysis System 9.3 edition for Windows (SAS Institute Inc., Cary, NC) was used for data analysis. The descriptive data were expressed as counts (percentages) for categorical variables and medians (interquartile ranges) for continuous variables. Univariable logistic regression was used to analyze the association of PTSD and every potential independent variable, including age, sex, BMI, smoke status, alcohol-drinking status, history of diseases (hypertension, diabetes mellitus, and heart disease), severe pneumonia, hypoalbuminemia, hepatic injury, other severe complications (acute kidney injury, respiratory failure, acute respiratory distress syndrome, arrhythmia, and cardiac insufficiency), CT score, and the number of involved pulmonary lobes, CURB-65 score, hospitalization days, OI, white blood cell count, lymphocyte count, hemoglobin, red blood cell count, fibrinogen, D-dimer, CRP, procalctin, albumin, ALT, AST, alkaline phosphatase, creatine kinase, creatine kinase isoenzyme, lactate dehydrogenase, myoglobin, creatinine, and urea nitrogen, separately. These variables were potential factors associated with PTSD (Lee et al., 2018; Wang et al., 2020). Stepwise logistic regression analysis with inclusion and exclusion criteria of p < .20 was performed to screen statistically significant the factors associated with PTSD (Chowdhury & Turin, 2020). No significant multicollinearity was found when the variance inflation factor was assessed. All tests were two-tailed and statistical significance was set as p < .05.
3 | RESULTS

Of the 144 participants with laboratory-confirmed COVID-19, the incidence of PTSD in all subjects was 16.0% (23/144). The incidence of PTSD was 9.72% (7/72) in males and 22.2% (16/72) in females, respectively. Baseline participant characteristics are displayed in Table 1.

The univariable and stepwise logistic regression analyses of possible risk factors and PTSD are shown in Table 2. In univariable logistic regression analysis, age above 40 years (OR [95% CI], 2.88 [1.11, 8.44]), female sex (OR [95% CI], 2.65 [1.05, 7.33]), current smoker (OR [95% CI], 4.40 [1.40, 12.9]), three or more involved pulmonary lobes (OR [95% CI], 4.40 [1.40, 19.3]), and a higher levels of urea nitrogen (OR [95% CI], 1.26 [1.04, 1.64]) were associated with a higher risk of PTSD, while a higher level of albumin (OR [95% CI], 0.89 [0.80, 0.97]) was associated with a lower risk of PTSD. In the stepwise logistic regression analysis, age above 40 years, female sex, current smoker, history of hypertension, three or more involved pulmonary lobes, and hemoglobin were identified as factors associated with PTSD, with ORs (95% CIs) of 4.42 (1.11, 20.2), 10.9 (2.04, 118.1), 60.09 (7.81, 232.55), 0.06 (0.00, 0.51), 4.70 (1.23, 19.9), 5.34 (1.09, 35.7), and 0.94 (0.87, 0.99), respectively.

4 | DISCUSSION

To our knowledge, this is the first prospective study to examine factors associated with PTSD in patients with confirmed COVID-19 infection. The results showed that older age, gender female, current smoking, and the number of involved pulmonary lobes (≥3), are risk factors for PTSD, while hypertension and high hemoglobin levels are inversely associated with the risk of PTSD.

In this study, 16.0% of COVID-19 patients had PTSD 3 months after infection. This incidence rate is higher than that reported for 41 COVID-19 patients at less than 1 month after symptom onset, where 12.2% had PTSD symptoms (Qi et al., 2020). A possible explanation might be that patients who were severely ill were excluded and PTSD was detected over the relatively short term in that study. However, the rate presented in our study was similar to that among nurses exposed to COVID-19 in Hubei, China, which showed that the incidence of PTSD was 16.83% (Wang et al., 2020). By contrast, a previous study reported that PTSD prevalence was 2.7% in home-quarantined college students 1 month after the outbreak of the COVID-19 epidemic (Tang et al., 2020). This difference corresponding to previous studies indicated that the prevalence of PTSD is higher among persons who are directly exposed to a disaster (Neria et al., 2008).

In the present study, older age and gender female are the main risk factors associated with PTSD in confirmed COVID-19 patients. In line with our results, a 4-year follow-up study indicated that survivors of SARS with PTSD were more likely to be older and female (Hong et al., 2009). In addition, a previous study conducted in confirmed COVID-19 patients indicated that COVID-19 patients with mental health problems were more likely to be female (Qi et al., 2020).

### TABLE 1 Characteristics of study participants

| Characteristics                              | n = 144 |
|----------------------------------------------|---------|
| PTSD, n (%)                                  | 23 (16.0) |
| Age ≥40y, n (%)                              | 77 (53.5) |
| Males, n (%)                                 | 72 (50.0) |
| Obesity (BMI ≥24 kg/m²), n (%)               | 72 (50.0) |
| Smoker, n (%)                                | 18 (12.5) |
| Drinker, n (%)                               | 110 (76.4) |
| Medical history, n (%)                       | 62.0 (41.3, 94.0) |
| Hypertension, n (%)                          | 38 (26.4) |
| Diabetes mellitus, n (%)                     | 72 (50.0) |
| Heart disease, n (%)                         | 4 (2.78) |
| Severe pneumonia, n (%)                      | 6.04 (0.96, 29.12) |
| Complications, n (%)                         | 93 (64.6) |
| Hypoalbuminemia, n (%)                       | 2.90 (2.26, 3.71) |
| Acute liver injury, n (%)                    | 2.65 (1.05, 7.33) |
| Other severe complications, n (%)            | 49 (34.0) |
| CT score ≥15, n (%)                          | 23 (16.0) |
| Involved pulmonary lobes ≥3, n (%)           | 93 (64.6) |
| Hospitalization days (d)                     | 14.0 (9.00, 20.5) |
| CURB-65 score ≥1, n (%)                      | 13 (9.0) |
| Oxygenation index                            | 425.0 (322.0, 506.0) |
| White blood cell count (10⁹/L)               | 4.65 (3.69, 5.85) |
| Lymphocyte count (10⁹/L)                     | 1.14 (0.85, 1.56) |
| Hemoglobin (g/L)                             | 133.0 (126.0, 48.0) |
| Red blood cell count (10¹²/L)                | 4.28 (3.94, 4.70) |
| Fibrinogen (g/L)                             | 2.90 (2.26, 3.71) |
| D-dimer (µg/mL)                              | 0.44 (0.25, 0.71) |
| CRP (mg/L)                                   | 6.04 (0.96, 29.12) |
| Procalcitonin (ng/mL)                        | 0.04 (0.04, 0.04) |
| Albumin (g/L)                                | 42.6 (39.3, 45.0) |
| Alanine aminotransferase (U/L)               | 33.5 (25.0, 47.0) |
| Aspartate aminotransferase (U/L)             | 29.0 (23.0, 38.0) |
| Alkaline phosphatase (U/L)                   | 61.0 (51.0, 82.0) |
| Creatine kinase (U/L)                        | 62.0 (41.0, 94.0) |
| Creatine kinase isoenzyme (ng/ml)            | 7.00 (5.00, 10.0) |
| Lactate dehydrogenase (U/L)                  | 483.0 (412.0, 595.0) |
| Myoglobin (µg/L)                             | 27.8 (19.4, 46.5) |
| Creatinine (µmol/L)                          | 55.0 (45.0, 68.0) |
| Urea nitrogen (mmol/L)                       | 4.00 (4.00, 5.00) |
| Interleukin-6 (pg/mL)                        | 4.10 (1.50, 15.0) |

Note: Continuous variables were described as medians (interquartile ranges), and categorical variables were described as counts (percentages). Abbreviations: BMI, body mass index; CRP, C-reactive protein, CT, computed tomography; PTSD, post-traumatic stress disorder.
| Factors                        | No. of subjects | No. of PTSD | OR (95% CI) a  | p-Value a  | OR (95% CI) b  | p-Value b  |
|-------------------------------|----------------|------------|----------------|------------|----------------|------------|
| Age                           |                |            |                |            |                |            |
| <40y                          | 67             | 6          | 1.00 (reference) | .04        | 1.00 (reference) | .04        |
| ≥40y                          | 77             | 17         | 2.88 (1.11, 8.44) | .04        | 4.42 (1.11, 20.2) | .02        |
| Sex                           |                |            |                |            |                |            |
| Males                         | 72             | 7          | 1.00 (reference) |            | 1.00 (reference) |            |
| Females                       | 72             | 16         | 2.65 (1.05, 7.33) |            | 10.9 (2.04, 118.1) |            |
| BMI (kg/m²)                   |                |            |                |            |                |            |
| <24                           | 72             | 10         | 1.00 (reference) | .50        | 1.00 (reference) | .59        |
| ≥24                           | 72             | 13         | 1.37 (0.56, 3.43) | .01        | 0.70 (0.19, 2.54) | <.001      |
| Smoker                        |                |            |                |            |                |            |
| No                            | 126            | 16         | 1.00 (reference) | .45        | 1.00 (reference) |            |
| Yes                           | 18             | 7          | 4.40 (1.40, 12.9) |            | 60.09 (7.81, 232.55) |            |
| Drinker                       |                |            |                |            |                |            |
| No                            | 34             | 4          | 1.00 (reference) | .65        |                |            |
| Yes                           | 110            | 19         | 1.57 (0.54, 5.72) |            |                |            |
| History of hypertension       |                |            |                |            |                |            |
| No                            | 122            | 19         | 1.00 (reference) | .76        | 1.00 (reference) | .02        |
| Yes                           | 22             | 4          | 1.21 (0.32, 3.67) |            | 0.06 (0.00, 0.51) |            |
| History of diabetes mellitus  |                |            |                |            |                |            |
| No                            | 134            | 22         | 1.00 (reference) | .60        |                |            |
| Yes                           | 10             | 1          | 0.57 (0.03, 3.24) |            |                |            |
| History of heart disease      |                |            |                |            |                |            |
| No                            | 140            | 22         | 1.00 (reference) | .62        |                |            |
| Yes                           | 4              | 1          | 1.79 (0.09, 14.7) |            |                |            |
| Severe pneumonia              |                |            |                |            |                |            |
| No                            | 139            | 21         | 1.00 (reference) | .16        | 1.00 (reference) | .11        |
| Yes                           | 5              | 2          | 3.75 (0.47, 23.93) |            | 7.97 (0.59, 114.29) |            |
| Hypoalbuminemia               |                |            |                |            |                |            |
| No                            | 132            | 20         | 1.00 (reference) | .38        |                |            |
| Yes                           | 12             | 3          | 1.87 (0.39, 6.90) |            |                |            |
| Acute liver injury            |                |            |                |            |                |            |
| No                            | 106            | 14         | 1.00 (reference) | .14        |                |            |
| Yes                           | 38             | 9          | 2.04 (0.78, 5.16) |            |                |            |
| Other severe complications    |                |            |                |            |                |            |
| No                            | 129            | 20         | 1.00 (reference) | .65        |                |            |
| Yes                           | 15             | 3          | 1.36 (0.29, 4.77) |            |                |            |
| CRP (mg/l)                    |                |            |                |            |                |            |
| <10                           | 95             | 14         | 1.00 (reference) | .57        |                |            |
| ≥10                           | 49             | 9          | 1.30 (0.50, 3.23) |            |                |            |
| CT score                      |                |            |                |            |                |            |
| <15                           | 121            | 17         | 1.00 (reference) | .16        |                |            |
| ≥15                           | 23             | 6          | 2.16 (0.70, 6.06) |            |                |            |

(Continues)
### TABLE 2 (Continued)

| Factors                              | No. of subjects | No. of PTSD OR (95% CI) | p-Value | OR (95% CI) | p-Value |
|--------------------------------------|-----------------|-------------------------|---------|-------------|---------|
| No. of involved pulmonary lobes      |                 |                         |         |             |         |
| <3                                   | 51              | 3                       | 1.00 (reference) | 1.00 (reference) | .02     |
| ≥3                                   | 93              | 20                      | 4.40 (1.40, 19.3) | 5.34 (1.09, 35.7) | .04     |
| Hospitalization days ≥15             |                 |                         | .34     |             |         |
| No                                   | 82              | 11                      | 1.00 (reference) |             | -       |
| Yes                                  | 62              | 12                      | 1.55 (0.63, 3.84) |             | -       |
| CURB-65 score ≥2                     |                 |                         | .47     |             |         |
| No                                   | 131             | 20                      | 1.00 (reference) |             | -       |
| Yes                                  | 13              | 3                       | 1.67 (0.35, 6.02) |             | -       |
| Oxygenation index                    | 144             | 23                      | 0.997 (0.99, 1.001) | .14     | -       |
| White blood cell count (10^9/L)      | 144             | 23                      | 1.19 (0.96, 1.46) | .10     | -       |
| Lymphocyte count (10^9/L)            | 144             | 23                      | 0.92 (0.37, 2.14) | .86     | -       |
| Hemoglobin (g/L)                     | 144             | 23                      | 0.98 (0.95, 1.006) | .13     | 0.94 (0.87, 0.99) | .03 |
| Red blood cell count (10^12/L)       | 144             | 23                      | 0.38 (0.13, 1.002) | .07     | -       |
| Fibrinogen (g/L)                     | 144             | 23                      | 1.39 (0.96, 2.01) | .08     | -       |
| D-dimer (µg/mL)                      | 144             | 23                      | 1.08 (0.48, 2.02) | .84     | -       |
| Procalcitonin (ng/mL)                | 144             | 23                      | 1.69 (0.02, 41.3) | .75     | -       |
| Albumin (g/L)                        | 144             | 23                      | 0.89 (0.80, 0.97) | .01     | -       |
| Alanine aminotransferase (U/L)       | 144             | 23                      | 0.99 (0.97, 1.01) | .50     | -       |
| Aspartate aminotransferase (U/L)     | 144             | 23                      | 1.002 (0.98, 1.02) | .88     | -       |
| Alkaline phosphatase (U/L)           | 144             | 23                      | 0.998 (0.99, 1.01) | .65     | -       |
| Creatine kinase (U/L)                | 144             | 23                      | 1.001 (0.998, 1.002) | .53     | -       |
| Creatine kinase isoenzyme (ng/ml)    | 144             | 23                      | 1.01 (0.99, 1.03) | .34     | 1.04 (0.99, 1.13) | .19 |
| Lactate dehydrogenase (U/L)          | 144             | 23                      | 1.001 (1.000, 1.003) | .11     | -       |
| Myoglobin (µg/L)                     | 144             | 23                      | 1.002 (0.999, 1.006) | .16     | -       |
| Creatinine (umol/L)                  | 144             | 23                      | 1.01 (0.99, 1.04) | .24     | -       |
| Urea nitrogen (mmol/L)               | 144             | 23                      | 1.26 (1.04, 1.64) | .04     | -       |
| Interleukin-6 (pg/mL)                | 144             | 23                      | 1.01 (0.99, 1.02) | .55     | -       |

Abbreviations: BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; CT, computed tomography; OR, odds ratio; PTSD, post-traumatic stress disorder.

*Univariable logistic regression analysis.
Stepwise logistic regression analysis.

Two additional studies also found that being female was a strong predictor of PTSD symptoms (Gonzalez-Sanguino et al., 2020; Liu et al., 2020). Similarly, animal studies have demonstrated different mood changes in rats related to sex, with female rats showing stronger emotional changes than their male counterparts (Yang et al., 2019). Collectively, these findings highlight that old age and gender female are the main risk factors associated with PTSD in confirmed COVID-19 patients.

To our knowledge, no studies have investigated how smoking influences PTSD. In the current prospective study, we observed that smoking was positively associated with PTSD in COVID-19 patients. Previous studies also suggested that smoking (nicotine) could cause poor mental health through neurotransmitter pathways (Picciotto et al., 2002; Plurphanswat et al., 2017). Moreover, evidence has suggested that quitting smoking was associated with a decrease in depressive symptoms (Rodriguez-Cano et al., 2016), which are strong risk factors for PTSD (Momma et al., 2014). Thus, the integration of stop smoking services into the PTSD care pathway would be a good way to improve mental health.

Multivariable logistic regression analysis indicated that the COVID-19 patients with ≥3 involved pulmonary lobes were more likely to have PTSD. Previous studies have suggested that COVID-19 patients with ≥3 involved pulmonary lobes had more severe illness (Dudoignon et al., 2020). This might be explained by the fact that a high incidence of PTSD was associated with the severity of exposure to disaster (Lee et al., 2018).
In our study, we found that a high hemoglobin level may act as a protective factor for PTSD in COVID-19 patients. This aligns with previous studies which documented that low hemoglobin level is a risk factor for postpartum PTSD (Sentilhes et al., 2017). These works also suggested that low baseline hemoglobin level strongly predicts incident depression (Trevisan et al., 2016). Taken together, this information suggests that anemia may contribute to PTSD in COVID-19 patients. Indeed, the current study also showed anemia was a risk factor for PTSD, with adjusted OR = 1.59 (95% CI: 0.48–4.59). Our findings suggest that discharged COVID-19 patients with high hemoglobin level had a low possibility of developing PTSD.

Interestingly, our study showed that baseline hypertension was inversely associated with the risk of PTSD. In contrast, a previous study demonstrated that a history of chronic illness was significantly associated with higher IES-R scores among the general population in China (Wang et al., 2020). Furthermore, an inverse association between hypertension and depression has been previously reported (Briggs et al., 2016). Nevertheless, the inverse association between hypertension and PTSD should be interpreted with caution as the proportion of COVID-19 patients with hypertension was small, resulting in low statistical power for this finding. Future research should investigate the role of hypertension in the development of PTSD using higher powered prospective studies.

To the best of our knowledge, there is no prospective study to identify the risk factors that develop PTSD in confirmed COVID-19 patients. In this study, we collected many variables at baseline, such as smoking status, drinking status, medical history, complications, clinical parameters, and blood parameters, which have allowed us to prospectively investigate the factors associated with PTSD in COVID-19 patients. Nevertheless, the present study has some limitations. First, PTSD was assessed by telephone follow-up. However, the follow-up was performed by a trained psychiatrist using a standardized interview technique. Second, although this is a prospective study, the baseline PTSD was not assessed. Third, we did not collect data on dietary intake, physical activity, and the history of psychiatry (depression, anxiety, schizophrenia, etc.), which might have affected the incidence of PTSD (Hall et al., 2015). In addition, either COVID-related or non-COVID-related interventions such as clinical and/or follow-up social support were not assessed in the study, so the residual confounding existed. Therefore, future research should be conducted to assess the effect of nutrition and exercise on PTSD. Fourth, our study had a relatively small size (144 patients) and a short follow-up time. Therefore, future large-scale prospective study with longer follow-up time is needed. Finally, our study sample was from a hospital in Tianjin, China, potentially limiting generalizability to hospital settings elsewhere.

In conclusion, the present study showed that the incidence of PTSD was not rare among patients with confirmed COVID-19 infection. We also found that older age, female sex, current smoking, and ≥3 involved pulmonary lobes were associated with increased risk of PTSD in COVID-19 patients, whereas hypertension and high hemoglobin level were inversely associated with risk of PTSD in COVID-19 patients.

ACKNOWLEDGMENTS
We thank all the people who have participated in this study.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
Data are available from the corresponding author (KN: nkj0809@gmail.com) upon reasonable request.

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1002/brb3.2492

ORCID
Jun Shen https://orcid.org/0000-0002-8738-0514
Kaijun Niu https://orcid.org/0000-0002-8772-2481

REFERENCES
Worldometer, (2020). https://www.worldometers.info/coronavirus/
Talevi, D., Socci, V, Carai, M., Carnaghi, G., Faleri, S., Trebbei, E., di Bernardo, A., Capelli, F., & Pacitti, F. (2020). Mental health outcomes of the CoVid-19 pandemic. Rivista di Psichiatria, 55(3), 137–144.
Vindegaard, N., & Benros, M. E. (2020). COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain, Behavior, and Immunity, 89, 531–542.
Pfefferbaum, B., & North, C. S. (2020). Mental health and the Covid-19 pandemic. The New England Journal of Medicine, 383, 510–512.
Bo, H. X., Li, W., Yang, Y., Wang, Y., Zhang, Q., Cheung, T., Wu, X., & Xiang, Y.-T. (2020). Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychological Medicine, 51(6),1052–1053.
Tsai, J., Harpaz-Rotem, I., Pietrzak, R. H., & Southwick, S. M. (2012). The role of coping, resilience, and social support in mediating the relation between PTSD and social functioning in veterans returning from Iraq and Afghanistan. Psychiatry, 75(2), 135–49.
Galea, S., Nandi, A., & Vlahov, D. (2005). The epidemiology of post-traumatic stress disorder after disasters. Epidemiologic Reviews, 27(1), 78–91.
Wu, K., & Wei, X. (2020). Analysis of psychological and sleep status and exercise rehabilitation of front-line clinical staff in the fight against covid-19 in china. Medical Science Monitor Basic Research, 26, e924085.
Wang, Y. X., Guo, H. T., Du, X. W., Song, W., Lu, C., & Hao, W. N. (2020). Factors associated with post-traumatic stress disorder of nurses exposed to corona virus disease 2019 in China. Medicine, 99(26), e20965.
Wang, C., Pan, R., Wan, X., Tan, Y., Xu, L., McIntyre, R. S., Choo, F. N., Tran, B., Ho, R., Sharma, V. K., & Ho, C. (2020). A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. Brain, Behavior, and Immunity, 87, 40–48.
Tang, W., Hu, T., Hu, B., Jin, C., Wang, G., Xie, C., Chen, S., & Xu, J. (2020). Prevalence and correlates of PTSD and depressive symptoms one month after the outbreak of the COVID-19 epidemic in a sample of home-quarantined Chinese university students. Journal of Affective Disorders, 274, 1–7.
Qi, R., Chen, W., Liu, S., Thompson, P. M., Zhang, L. J., Xia, F., Cheng, F., Hong, A., Surento, W., Luo, S., Sun, Z. Y., Zhou, C. S., Li, L., Jiang, X., & Lu, G. M. (2020). Psychological morbidities and fatigue in patients with confirmed COVID-19 during disease outbreak: Prevalence and associated biopsychosocial risk factors. medRxiv: the preprint server for health sciences.
Lee, S. H., Kim, E. J., Noh, J. W., & Chae, J. H. (2018). Factors associated with post-traumatic stress symptoms in students who survived 20 months...
after the sewol ferry disaster in Korea. Journal of Korean Medical Science, 33(11), e90.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ..., & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506.

Information MH. Post-Traumatic Stress Disorder. (2021). https://www.nimh.nih.gov/health/publications/post-traumatic-stress-disorder-ptsd

Rash, C. J., Coffey, S. F., Baschnagel, J. S., Drobes, D. J., & Saladin, M. E. (2008). Psychometric properties of the IES-R in traumatized substance dependent individuals with and without PTSD. Addictive Behaviors, 33(8), 1039–1047.

Wu, K. K., & Chan, K. S. (2003). The development of the Chinese version of impact of event scale—revised (CIES-R). Social Psychiatry and Psychiatric Epidemiology, 38(2), 94–98.

Lim, W. S., van der Eerden, M. M., Laing, R., Boersma, W. G., Karalus, N., Town, G. I., Lewis, S. A., & Macfarlane, J. T. (2003). Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax, 58(5), 377–382.

Hansell, D. M., Bankier, A. A., MacMahon, H., McLeod, T. C., Muller, N. L., & Remy, J. (2008). Fleischner Society: Glossary of terms for thoracic imaging. Radiology, 246(3), 697–722.

Pan, F., Ye, T., Sun, P., Gui, S., Liang, B., Li, H., Zheng, D., Wang, J., Hesketh, R. L., Yang, L., & Zheng, C. (2020). Time course of lung changes at ct during recovery from coronavirus disease 2019 (COVID-19). Radiology, 295(3), 715–721.

Chang, Y. C., Yu, C. J., Chang, S. C., Galvin, J. R., Liu, H. M., Hsiao, C. H., Kuo, P.-H., Chen, K.-Y., Franks, T. J., Huang, K.-M., & Yang, P.-C. (2005). Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: Evaluation with thin-section CT. Radiology, 236(3), 1067–1075.

Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Dowell, S. F., File, T. M., Musher, D. M., Niederman, M. S., Torres, A., & Whitney, C. G. (2007). Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases, 44(Suppl 2), S27–72.

Egbert, R. C., Bouck, T. T., Gupte, N. N., Pena, M. M., Dang, K. H., Ornell, S. S., & Rash, C. J., Coffey, S. F., Baschnagel, J. S., Drobes, D. J., & Saladin, M. E. (2008). Psychometric properties of the IES-R in traumatized substance dependent individuals with and without PTSD. Addictive Behaviors, 33(8), 1039–1047.

Wu, K. K., & Chan, K. S. (2003). The development of the Chinese version of impact of event scale—revised (CIES-R). Social Psychiatry and Psychiatric Epidemiology, 38(2), 94–98.

Hong, X., Currier, G. W., Zhao, X., Jiang, Y., Zhou, W., & Wei, J. (2009). Post-traumatic stress disorder in convalescent severe acute respiratory syndrome patients: A 4-year follow-up study. General Hospital Psychiatry, 31(6), 546–554.

Chowdhury, M. Z. I., & Turin, T. C. (2020). Variable selection strategies and its importance in clinical prediction modelling. Family Medicine and Community Health, 8(1), e000262.

Neria, Y., Nandi, A., & Galea, S. (2008). Post-traumatic stress disorder following disasters: A systematic review. Psychological Medicine, 38(4), 467–480.

How to cite this article: Mei, Z., Wu, X., Zhang, X., Zheng, X., Li, W., Fan, R., Yu, H., Zhang, S., Gu, Y., Wang, X., Xia, Y., Meng, Ge, Shen, J., & Niu, K. (2022). The occurrence and risk factors associated with post-traumatic stress disorder among discharged COVID-19 patients in Tianjin, China. Brain and Behavior, 12, e2492. https://doi.org/10.1002/brb3.2492